Dissecting Target Toxic Tissue and Tissue Specific Responses of Irinotecan in Rats Using Metabolomics Approach
暂无分享,去创建一个
Jing Wang | Yong Wang | Fengguo Xu | Yin Huang | Jing Wang | Fengguo Xu | Zunjian Zhang | Jiaqing Chen | Pei Zhang | Yong Wang | Yin Huang | Pei Zhang | Jiaqing Chen | Zunjian Zhang | Yiran Yao | Yi-Fan Yao
[1] J. H. Park,et al. Effects of dietary linoleic acid on mucosal adaptation after small bowel resection. , 1989, Digestion.
[2] J. Nicholson,et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. , 2010, Journal of proteome research.
[3] Elaine Holmes,et al. Magic angle spinning NMR and 1H-31P heteronuclear statistical total correlation spectroscopy of intact human gut biopsies. , 2008, Analytical chemistry.
[4] R. Green,et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet , 2008 .
[5] J. Palis,et al. “Liver function tests” are not always tests of liver function , 2001, American journal of hematology.
[6] D. Vance,et al. The role of phosphatidylcholine biosynthesis in the secretion of lipoproteins from hepatocytes. , 1985, Canadian journal of biochemistry and cell biology = Revue canadienne de biochimie et biologie cellulaire.
[7] Joseph V Bonventre,et al. Next-generation biomarkers for detecting kidney toxicity , 2010, Nature Biotechnology.
[8] D. Palmer,et al. Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes. , 2013, Critical reviews in oncology/hematology.
[9] R. Tsang,et al. Chemotherapy-Associated Steatohepatitis with Temozolomide and Dexamethasone , 2012, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[10] Naoki Tanaka,et al. Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression. , 2016, Toxicology and applied pharmacology.
[11] J. Cha,et al. Alleviation of Fatty Liver by α-Linolenic Acid , 2004 .
[12] Yingdong Zhao,et al. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment , 2011, BMC Medical Genomics.
[13] M. Ratain,et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.
[14] S. Guichard,et al. © 1999 Cancer Research Campaign Article no. bjoc.1998.0364 CPT-11 converting carboxylesterase and topoisomerase I , 2022 .
[15] R. Rodrigo,et al. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. , 2004, Free radical biology & medicine.
[16] N. Araníbar,et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. , 2013, Toxicology and applied pharmacology.
[17] P. Yeagle. Lipid regulation of cell membrane structure and function , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] W. Guo,et al. Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues. , 2005, Journal of chromatography. A.
[19] J Verweij,et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] M. Dolan,et al. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. , 2000, Cancer research.
[21] A. Nanji,et al. Dietary saturated fatty acids: a novel treatment for alcoholic liver disease. , 1995, Gastroenterology.
[22] K. Katano,et al. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer , 2011, Surgery Today.
[23] B. Levine,et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. , 2002, Cancer research.
[24] Yung-chi Cheng,et al. The Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced Gastrointestinal Toxicity , 2010, Science Translational Medicine.
[25] D. Piomelli,et al. The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.
[26] P. Potter,et al. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. , 2011, Biochemical pharmacology.
[27] R. A. van den Berg,et al. Centering, scaling, and transformations: improving the biological information content of metabolomics data , 2006, BMC Genomics.
[28] D. Vance,et al. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. , 1988, The Journal of biological chemistry.
[29] M. Shimada,et al. Irinotecan injures tight junction and causes bacterial translocation in rat. , 2012, The Journal of surgical research.
[30] Vickie E. Baracos,et al. Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats , 2012, PloS one.
[31] Jing Wang,et al. Metabolomic study of Chinese medicine Huang Qin decoction as an effective treatment for irinotecan-induced gastrointestinal toxicity , 2015 .
[32] F. Cunha,et al. Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation , 2012, Cancer Chemotherapy and Pharmacology.
[33] E. Distrutti,et al. The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity1 , 2009, The Journal of Immunology.
[34] J. Sjövall,et al. Bile acid metabolism. , 1975, Annual review of biochemistry.
[35] M Nomura,et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.
[36] G D Buffinton,et al. Altered ascorbic acid status in the mucosa from inflammatory bowel disease patients. , 1995, Free radical research.
[37] Huiru Tang,et al. Metabonomic analysis reveals the CCl4-induced systems alterations for multiple rat organs. , 2012, Journal of proteome research.
[38] R. Ribeiro,et al. Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model , 2014, Cancer Chemotherapy and Pharmacology.
[39] Dae-Joong Kang,et al. Bile salt biotransformations by human intestinal bacteria Published, JLR Papers in Press, November 18, 2005. , 2006, Journal of Lipid Research.
[40] M. Lukáš,et al. Bile acid malabsorption in inflammatory bowel disease: Assessment by serum markers , 2011, Inflammatory bowel diseases.
[41] B. Spyropoulos,et al. Interleukin‐18 as a target for modulation of irinotecan‐induced intestinal toxicity: a step towards a better therapeutic index?: Commentary on Lima‐Junior et al., Br J Pharmacol 171: 2335–2350 , 2014, British journal of pharmacology.
[42] J. Hankiewicz,et al. [Liver function tests]. , 1976, Wiadomosci lekarskie.